Bruker Biosciences Corp - Additional Proxy Soliciting Materials (definitive) (DEFA14A)
18 January 2008 - 7:44AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 17, 2008
BRUKER BIOSCIENCES CORPORATION
(Exact name of
registrant as specified in its charter)
Delaware
|
|
000-30833
|
|
04-3110160
|
(State or other
jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
40
Manning Road
Billerica, MA 01821
(Address of
principal executive offices)(Zip Code)
Registrants
telephone number, including area code:
(978) 663-3660
Check
the appropriate box if the Form 8-K filing is intended to simultaneously
satisfy the reporting obligation of the registrant under any of the following
provisions:
o
Written communications pursuant to Rule 425 under
the Securities Act
x
Soliciting material pursuant to Rule 14a-12 of the
Exchange Act
o
Pre-commencement communications pursuant to Rule 14d-2(b) Exchange
Act
o
Pre-commencement communications pursuant to Rule 13e-4(c) Exchange
Act
Item
8.01. Other Events
On January 17, 2008,
Bruker BioSciences Corporation issued a press release announcing that it has
filed with the Securities and Exchange Commission its definitive proxy
statement relating to the proposed acquisition of the Bruker BioSpin group of
companies, and that a special meeting of stockholders to consider and vote upon
matters relating to the acquisition will be held on February 25, 2008.
Bruker BioSciences also announced that the required waiting period imposed by
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has
expired.
A copy of the press
release is filed as Exhibit 99.1 to this Current Report on Form 8-K,
and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d)
Exhibits.
Exhibit No.
Description of Exhibit
99.1
Press Release dated January 17,
2008.
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
BRUKER BIOSCIENCES
CORPORATION
|
|
(Registrant)
|
|
|
Date: January 17, 2008
|
By:
|
/s/ Frank H.
Laukien
|
|
|
Frank H.
Laukien, Ph.D.
Chief Executive Officer and President
|
|
|
|
3
Exhibit Index
Exhibit
Number
|
|
Exhibit Name
|
99.1
|
|
Press Release dated
January 17, 2008.
|
4
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024